BioSpace News Archive

Science 37 Holdings, Inc., the industry-leading Metasite™, announced the granting of inducement equity awards under the Science 37 Holdings, Inc. 2022 Employment Inducement Incentive Award Plan.

Crinetics Pharmaceuticals, Inc. announced that on February 10, 2023, the Compensation Committee of Crinetics’ Board of Directors granted non-qualified stock option awards to purchase an aggregate of 90,000 shares of its common stock to six new non-executive employees under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan.

Fulcrum Therapeutics, Inc.®, a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, announced that the Company granted non-statutory stock options to new employees.

Tetra Bio-Pharma Inc. announced that its common shares began trading on the OTC Markets Group’s OTCPink Market in the United States under the symbol “TBPMF” effective at the opening of trading on Friday, February 10, 2023 and will continue to trade on the Toronto Stock Exchange under the ticker symbol “TBP”.

Mirum Pharmaceuticals, Inc. announced that on February 10, 2023, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 5,000 shares of common stock and 2,500 restricted stock units to one new employee under Mirum’s 2020 Inducement Plan.

Genentech, a member of the Roche Group, announced positive new data from two global Phase III studies, BALATON and COMINO, evaluating Vabysmo® in macular edema due to branch and central retinal vein occlusion at 24 weeks.

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that results from the phase 2 trial evaluating the efficacy and safety of oral sebetralstat for the on-demand treatment of hereditary angioedema (HAE) attacks has been published in the international weekly medical journal, The Lancet.

Sensient Technologies Corporation reported consolidated revenue of $348.7 million in this year’s fourth quarter compared to $340.4 million in last year’s fourth quarter.

Orchard Therapeutics, a global gene therapy leader, announced that it plans to change the ratio of its American Depositary Shares to its ordinary shares, nominal value £0.10 per share, from the current ADS Ratio of one ADS to one ordinary share to a new ADS Ratio of one ADS to ten ordinary shares.

Aligos Therapeutics, Inc. (Nasdaq: ALGS) today announced that Lawrence M. Blatt, Ph.D., MBA, Chairman and CEO of Aligos, will present at the virtual SVB Securities Global Biopharma Conference on Wednesday, February 15, 2023 at 5:00 p.m. ET.